Key result
Bivalirudin fails to reduce death, MI, or major bleeding vs heparin monotherapy during PCI for MI.
Why the study?
Does bivalirudin reduce the composite of death, myocardial infarction, or major bleeding in patients undergoing PCI for myocardial infarction compared to heparin monotherapy?
RCT
Does bivalirudin reduce the composite of death, myocardial infarction, or major bleeding in patients undergoing PCI for myocardial infarction compared to heparin monotherapy?
In patients undergoing PCI for myocardial infarction, bivalirudin does not provide a significant advantage over heparin monotherapy for the composite of death, MI, or major bleeding.
Answers are grounded in this paper and cite their sources.
Bivalirudin does not reduce the composite endpoint versus heparin in MI PCI; reinforces heparin monotherapy as standard and challenges routine bivalirudin preference.
Among patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy. (Funded by the Swedish Heart-Lung Foundation and others; VALIDATE-SWEDEHEART ClinicalTrialsRegister.eu number, 2012-005260-10 ; ClinicalTrials.gov number, NCT02311231 .).
No takes yet. Share an insight, caveat, or question.
Erlinge et al. (2017) conducted an RCT in Myocardial infarction undergoing PCI. Bivalirudin vs. Heparin monotherapy was evaluated on Composite of death from any cause, myocardial infarction, or major bleeding. Bivalirudin did not lower the rate of the composite of death from any cause, myocardial infarction, or major bleeding compared with heparin monotherapy among patients undergoing PCI for MI.
Synapse has enriched 10 related papers. Consider them for comparative context: